Signals Blog
Menu

Ubaka Ogbogu

Ubaka Ogbogu is an Assistant Professor and the Katz Group Research Fellow in Health Law at the Faculty of Law, University of Alberta. His teaching and research interests include health law, law and biotechnology, law and bioethics, science and regulation, and legal history. Ubaka is a former SCN trainee and a recipient of the SCN Canadian Alumni Award. He has done extensive research work on the ethical, legal and social issues associated with stem cell research, and continues to research and publish in this area. Ubaka holds law degrees at the bachelors and masters levels from the University of Benin in Nigeria and the University of Alberta, and is currently in the process of completing a doctorate in law at the University of Toronto. His doctoral work focuses on the legal history of early health care and biotechnology policies in Canada, particularly in relation to smallpox vaccination and infectious diseases.

Posts by: Ubaka


Stem cell pseudoscience in the courts?

Patients contemplating medical travel for the purpose of receiving scientifically unproven stem cell treatments may wish to consider one more potential side effect: the possibility of losing their eligibility for health status-related compensation and benefits. In May 2012, a United States appeal court affirmed an earlier New York district court decision to deny disability and […]

Federal Government proposes amendments to Canada’s embryo research law

The Federal Government has proposed amendments to the Assisted Human Reproduction Act, the legislation that governs embryo research, including many aspects of stem cell research. The amendments, which are contained in an omnibus budget implementation bill tabled before Parliament on April 26, seeks primarily to implement the 2010 Supreme Court of Canada ruling that invalidated […]

EU stem cell patent ruling: too early to predict impact

The Court of Justice of the European Union (ECJ) ruled this week that scientific research patents cannot be granted for human embryonic stem cell products under European Union (EU) law. The patent in issue, held by Dr. Oliver Brüstle, Director of the Institute of Reconstructive Neurobiology at the University of Bonn, concerns isolated and purified […]

US Appeal Court reinstates Obama’s funding policy on stem cell research

A few months ago I wrote about a temporary injunction (ban) issued by United States federal district court judge Royce C. Lamberth on federal funding for research on human embryonic stem cell lines derived from supernumerary IVF embryos. Subsequently, at the request of the federal government, a U.S. appeal court suspended the injunction pending a […]

Integrating stem cell technologies into health care: It’s time to get our priorities straight

While preparing a consulting report on ethical issues associated with priority setting (a.k.a. resource allocation, rationing) in the stem cell research context, I was surprised to find that there are no published Canadian studies of priority-setting matters pertaining specifically to stem cell research or stem cell-based technologies. A search of the Canadian Institutes of Health […]